Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population.
Methods The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan.
Result s: Of 2,015 hemodialysis patients screened in 2019, 169 patients seropositive for HCV RNA were enrolled (mean age, 65.6 years; median duration of hemodialysis, 5.8 years). All patients received at least one comedication (median number, 6; mean class number, 3.4). The most common comedication classes were ESRD-associated medications (94.1%), cardiovascular drugs (69.8%) and antidiabetic drugs (43.2%). ESRD-associated medications were excluded from DDI analysis. Sofosbuvir/velpatasvir/voxilaprevir had the highest frequency of potential contraindicated DDIs (red, 5.6%), followed by glecaprevir/pibrentasvir (4.0%), sofosbuvir/ledipasvir (1.3%), sofosbuvir/velpatasvir (1.3%), and elbasvir/grazoprevir (0.3%). For potentially significant DDIs (orange, requiring close monitoring or dose adjustments), sofosbuvir/velpatasvir/voxilaprevir had the highest frequency (19.9%), followed by sofosbuvir/ledipasvir (18.2%), glecaprevir/pibrentasvir (12.6%), sofosbuvir/velpatasvir (12.6%), and elbasvir/grazoprevir (7.3%). Overall, lipid-lowering agents were the most common comedication class with red-category DDIs to all DAA regimens (n=62), followed by cardiovascular agents (n=15), and central nervous system agents (n=10).
Conclusions HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. Elbasvir/grazoprevir had the fewest potential DDIs, and sofosbuvir/velpatasvir/voxilaprevir had the most potential DDIs.
Citations
Citations to this article as recorded by
Predictive value of osteoprotegerin and heart fatty acid binding protein as biomarkers for heart failure in chronic kidney disease patients on hemodialysis: A case-control study Saddam Jaber Khudiar, Rayah Sulaiman Baban, Arif Sami Malik Journal of Research in Pharmacy.2025; 29(2): 682. CrossRef
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai Clinical and Molecular Hepatology.2025; 31(3): 899. CrossRef
Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan Chung-Feng Huang, Po-Cheng Liang, Yu-Ju Wei, Chao-Chun Wu, Shi-Lun Wei, Li-Ju Lin, Pei-Chun Hsieh, Tsui-Hsia Hsu, Maggie Shu-Mei Hsu, Ya-Xin Luo, Hsi-Chieh Chen, Tsu-Yun Ho, Shao-Hsuan Lin, Chia-Ling Liu, Kuo-Pen Cheng, John W. Ward, Ming-Lung Yu Journal of the Formosan Medical Association.2025; 124: S102. CrossRef
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao Expert Opinion on Pharmacotherapy.2024; 25(12): 1691. CrossRef
Comorbidities and Contraindicated Medications in Patients with Chronic Hepatitis C Infection in Japan: a Real-World Database Study Takeya Tsutsumi, Hiroshi Yotsuyanagi Kanzo.2024; 65(8): 368. CrossRef
Enhancing hepatitis C management in ESRD: Evaluating efficacy and safety of alternative antiviral regimens Ume Aiman, Umer Bin Shahzad Therapeutic Apheresis and Dialysis.2024; 28(6): 967. CrossRef
TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes Ming-Lung Yu, Chih-Yuan Wang, Mei-Hsuan Lee, Horng-Yih Ou, Pin-Nan Cheng, Shih-Te Tu, Jee-Fu Huang, Jung-Fu Chen, Tsung-Hui Hu, Chih-Cheng Hsu, Jia-Horng Kao, Chien-Jen Chen, Han-Chieh Lin, Chien-Ning Huang Journal of the Formosan Medical Association.2023; 122(3): 202. CrossRef
Drug–Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed Oliver Scherf-Clavel Therapeutic Drug Monitoring.2022; 44(2): 253. CrossRef
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 Chen-Hua Liu, Jia-Horng Kao Hepatology International.2022; 16(5): 1001. CrossRef
Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report Mario Enrico Canonico, Giuseppe Damiano Sanna, Roberta Siciliano, Fernando Scudiero, Giovanni Esposito, Guido Parodi Frontiers in Pharmacology.2022;[Epub] CrossRef
Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents Tyler Shugg, Nicholas R. Powell, Patrick J. Marroum, Todd C. Skaar, Islam R. Younis Clinical Pharmacology & Therapeutics.2022; 112(5): 1088. CrossRef
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study Vicki Wing-Ki Hui, Christopher Langjun Au, Amy Shuk Man Lam, Terry Cheuk-Fung Yip, Yee-Kit Tse, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Grace Lai-Hung Wong Hepatology International.2022; 16(6): 1318. CrossRef
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy Chung-Feng Huang, Yu-Ju Wei, Yu-Tse Wu, Yi-Wen Chiu, Ming-Lung Yu Journal of Hepatology.2021; 75(4): 1006. CrossRef
First
Prev
